» Authors » Nicholas S Hill

Nicholas S Hill

Explore the profile of Nicholas S Hill including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 254
Citations 4850
Followers 0
Related Specialties
Top 10 Co-Authors
Published In
Affiliations
Soon will be listed here.
Recent Articles
1.
Tariq A, Ghamloush M, Schumaker G, Faugno A, Price L, Lussier L, et al.
Respir Med Res . 2025 Feb; 87:101156. PMID: 39923497
Background: The use of high flow nasal oxygen therapy (HFNO) may improve clinical outcomes in acute hypoxemic respiratory failure (AHRF) compared to conventional oxygen. However, whether the use of HFNO...
2.
Mukherjee M, Mathai S, Jellis C, Freed B, Yanek L, Agoglia H, et al.
Circ Cardiovasc Imaging . 2024 Dec; 17(10). PMID: 39691460
Background: Defining qualitative grades of echocardiographic metrics of right heart chamber size and function is critical for screening, clinical assessment, and measurement of therapeutic response in individuals with pulmonary vascular...
3.
Farmer M, Callahan C, Hughes A, Riska K, Hill N
CHEST Pulm . 2024 Nov; 2(3). PMID: 39575446
Background: When administered as first-line intervention to patients admitted with acute hypercapnic respiratory failure secondary to COPD exacerbation in conjunction with guideline-recommended therapies, noninvasive ventilation (NIV) has been shown to...
4.
Hernandez G, Hill N
Curr Opin Crit Care . 2024 Nov; 31(1):93-100. PMID: 39526695
Purpose Of Review: Postextubation respiratory support treatment approaches, indications, and subgroups of patients with different responses to those therapies are rapidly changing. Planning optimal therapy in terms of choosing devices,...
5.
Shelburne N, Nian H, Beck G, Casanova N, Desai A, DuBrock H, et al.
CHEST Pulm . 2024 Nov; 2(3). PMID: 39524046
Background: Sex-based differences are important in the development and progression of pulmonary arterial hypertension. However, it is not established whether these differences are generalizable to all forms of pulmonary hypertension...
6.
Reddy Y, Frantz R, Hassoun P, Hemnes A, Horn E, Leopold J, et al.
J Am Coll Cardiol . 2024 Oct; 84(22):2196-2210. PMID: 39453363
Background: Patients with group 1 pulmonary hypertension (PH) and risk factors for heart failure with preserved ejection fraction (HFpEF) demonstrate worse response to pulmonary vasodilator therapy. The mechanisms and optimal...
7.
Burns K, Wong J, Rizvi L, Lafreniere-Roula M, Thorpe K, Devlin J, et al.
JAMA . 2024 Oct; 332(21):1808-1821. PMID: 39382222
Importance: The optimal screening frequency and spontaneous breathing trial (SBT) technique to liberate adults from ventilators are unknown. Objective: To compare the effects of screening frequency (once-daily screening vs more...
8.
Reddy Y, Dubrock H, Hassoun P, Hemnes A, Horn E, Leopold J, et al.
Eur J Heart Fail . 2024 Jul; 26(11):2323-2336. PMID: 39058211
Aims: The clinical utility of pulmonary hypertension (PH) risk scores in non-group 1 PH with pulmonary vascular disease (PVD) remains unresolved. Methods And Results: We utilized the prospective multicenter PVDOMICS...
9.
Strick D, Farber H, Hill N, Preston I, Pradhan N, Malla B
Chest . 2024 Jul; 166(1):e1-e3. PMID: 38986644
Group 5 pulmonary hypertension (PH) encompasses diverse diseases, with a few cases linking it to T-cell large granular lymphocytic (LGL) leukemia. We report a case of a 76-year-old woman, diagnosed...
10.
Moon B, Zhou I, Ning Y, Chen Y, Le Fur M, Shuvaev S, et al.
J Am Heart Assoc . 2024 Jul; 13(14):e034363. PMID: 38979786
Background: Aging-associated left ventricular dysfunction promotes cardiopulmonary fibrogenic remodeling, Group 2 pulmonary hypertension (PH), and right ventricular failure. At the time of diagnosis, cardiac function has declined, and cardiopulmonary fibrosis...